Volume Spike Investor

Anadys Pharma (NASDAQ: ANDS) may not be one of the exponential runners, but there is action here this morning.  The company announced that its ANA773 demonstrated significant antiviral response in early clinical trial in Hepatitis C patients in the Phase I clinical trial of ANA773, its oral inducer of endogenous interferons that acts via the toll-like receptor 7 pathway. At 8:03 AM EST we have shares up 31% at $3.14 on over 100,000 shares.  Average volume here is around 1 million shares per day; expect that volume to be hit very early.